Free Trial
LON:HLN

Haleon 7/31/2025 Earnings Report

Haleon logo
GBX 355.20 +2.20 (+0.62%)
As of 08/8/2025 11:57 AM Eastern

Haleon EPS Results

Actual EPS
GBX 8.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Haleon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Haleon Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Haleon Earnings Headlines

Haleon plc (NYSE:HLN) Q2 2025 Earnings Call Transcript
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Haleon (LON:HLN) Has Announced A Dividend Of £0.022
Haleon slides Thursday, underperforms market
See More Haleon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haleon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haleon and other key companies, straight to your email.

About Haleon

Haleon (LON:HLN) (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

View Haleon Profile

More Earnings Resources from MarketBeat